SCHEMBL13102496

SCHEMBL13102496

CCc1nc2c(F)cccc2c(=O)n1NC(=O)Cc1cccc(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.40
CASP7 P55210 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SRC P12931 1/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PRKACA P17612 1/20 0.39
ROCK1 Q13464 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
GLS O94925 1/20 0.39
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AADAT Q8N5Z0 1/20 0.38
TRPC5 Q9UL62 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102404 0.90 NPSR1 (0.49) NPSR1ALDH1A1HTTLMNAMEN1
SCHEMBL13101705 0.90 ALDH1A1 (0.43) CASP3CASP7NPSR1ALDH1A1SRC
SCHEMBL13101706 0.90 ALDH1A1 (0.44) NPSR1ALDH1A1HTTLMNAMEN1
SCHEMBL13102405 0.89 ALDH1A1 (0.45) NPSR1ALDH1A1HTTLMNAMEN1
SCHEMBL13101953 0.89 TRPV1 (0.43) CASP3CASP7NPSR1ALDH1A1SRC
SCHEMBL13101713 0.88 KDM4E (0.50) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL13102208 0.88 LMNA (0.54) NPSR1ALDH1A1SRCHTTLMNA
SCHEMBL13102247 0.87 SRC (0.46) CASP3CASP7NPSR1ALDH1A1SRC
SCHEMBL13102090 0.86 TRPV1 (0.39) CASP3CASP7NPSR1ALDH1A1SRC
SCHEMBL13102109 0.85 LMNA (0.43) NPSR1ALDH1A1HTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 CASP3 1298/4885CASP7 828/4885NPSR1 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.